10, 2010 /PRNewswire/ -- Results from the first head-to-head taste test of oral contrast agents indicate a significantly greater preference for diluted iohexol (Omnipaque(TM)) than for diluted diatrizoate sodium (Gastroview(TM)) among patients undergoing abdominal-pelvic computed tomography (CT) scanning.
Our study showed a statistically significant taste preference for the low-osmolar contrast agent iohexol over the high-osmolar diatrizoate sodium, with no significant differences between agents in terms of side effects or bowel opacification," said Michelle M.
McNamara and colleagues conducted a prospective, double-blinded study in which 300 adult patients undergoing routine abdominal-pelvic CT were randomized to receive either iohexol (n=149) or diatrizoate sodium (n=151).
A total of 233 patients (81%) preferred iohexol, compared to 54 patients (19%) who preferred diatrizoate sodium (p<0.
